- On Announcement of All Oral MDR TB regimen by Indian Government
- Modi visit to US: Trump appearance signals importance of India
- After ‘Howdy Modi’, Trump and Modi likely to sign trade deal
- US – India Relations: President Trump To Sign New Trade Deal With Indian PM Modi?
- India-US trade talks: Trading lives?
Category Archives: Biologics/Biosimilars
Source: Irish Times 17th April, 2019 Health service could save €50m by using biosimilar medicines, says Michael Barry Prof Michael Barry has told a conference the pricing structures of pharmaceutical companies are unsustainable. Photograph: PA Wire Just six patients … Continue reading
Source: Pharmaletter 3rd Oct 2018, New Delhi The pharmaceutical intellectual property aspects of the United States-Mexico-Canada Agreement (USMCA), which was agreed on Monday to replace the former North American Free Trade Agreement (NAFTA) accord, have come in for criticism from the … Continue reading
by Fran Quigley, Health & Human Rights Journal | June 26, 2018 Access to essential medicines is a well-established component of the human right to health, but it is a right that remains elusive for millions of people across the globe. The … Continue reading
Humira is the best-selling prescription drug in the world. You may have seen the commercials. Because of Humira, a woman with rheumatoid arthritis can wash her puppy in the bathtub, another with colitis can stroll happily through a fair packed … Continue reading
Rethinking IP in the TPP: Canadian Government Plays Key Role in Suspending Unbalanced Patent and Copyright Rules
Source: http://www.michaelgeist.ca/2017/11/rethinking-ip-in-the-tpp/ Years of disappointment in trade negotiations have left many Canadian intellectual property watchers hoping for the best, but expecting the worst when it comes to the IP provisions in trade deals. In earlier talks, Canadian negotiators would often advocate … Continue reading
Source: Conversation.com |November 9, 2017 Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend. The latest plan to get the controversial trade deal up and running … Continue reading
Over Humira’s lifetime, AbbVie has secured more than 100 patents to prevent anyone from attempting to copy the biologic, with $16 billion in annual sales. By Cynthia Koons Humira, a treatment for inflammatory diseases such as rheumatoid arthritis and psoriasis … Continue reading